Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge
Authors:
Open Access
- 13 August 2025
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1619450
Abstract
Background: It has been reported that immunotherapy with programmed cell death protein 1 (PD-1) inhibitors (pembrolizumab or nivolumab) can induce multiple eruptive keratoacanthomas (KAs), representing an immune-related cutaneous adverse event (ircAE).Methods: This case report describes a 63-year-old female with recurrent cervical adenocarcinoma who developed multiple eruptive KAs and a concurrent fungal infection following treatment with the PD-1 inhibitor zimberelimab. We analyzed the etiology, diagnosis, and treatment by integrating clinical manifestations, pathological examinations, previous treatment history, and a review of the literature.Results: Despite an initial misdiagnosis as a fungal infection, multidisciplinary review identified KA as an ircAE. Topical corticosteroids led to resolution, and another PD-1 inhibitor was reintroduced without recurrence of cutaneous toxicity.Conclusion: This is the first documented case of eruptive KA linked to zimberelimab, expanding the spectrum of PD-1 inhibitor-associated ircAEs. A concurrent fungal infection obscured the diagnosis, delaying appropriate treatment and highlighting the importance of recognizing rare ircAEs and multidisciplinary collaboration.Keywords
This publication has 17 references indexed in Scilit:
- Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor UseJAMA Dermatology, 2024
- Multiple Eruptive Keratoacanthomas Secondary to Nivolumab ImmunotherapyJournal of Immunotherapy, 2023
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Formation of eruptive cutaneous squamous cell carcinomas after programmed cell death protein-1 blockadeJAAD Case Reports, 2020
- Treatment of PD-1/PD-L1 Inhibitor–Induced Dermatitis Resolves Concomitant Eruptive KeratoacanthomasJAMA Dermatology, 2020
- Pembrolizumab‐induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planusJournal of Cutaneous Pathology, 2019
- Eruptive squamous cell carcinomas in metastatic melanoma: An unintended consequence of immunotherapyJAAD Case Reports, 2019
- Transient eruptive keratoacanthomas associated with nivolumabJAAD Case Reports, 2019
- Eruptive Keratoacanthomas Associated With Pembrolizumab TherapyJAMA Dermatology, 2017
- Keratoacanthoma (KA): An update and reviewJournal of the American Academy of Dermatology, 2016